Clinical Trial Update: The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study evaluating oxcarbazepine for agitation and aggression in dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• Oxcarbazepine (Oxcarbazepine)

Snippet

Sponsor: Sykehuset Innlandet HF | Conditions: Agitation Aggression in Dementia | Phase 3 | Status: COMPLETED